Showing results (101-110 of 155) with videos related to
Sort By:
Pageof 16
Journal of Clinical Medicine|December 2, 2020
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving AtezolizumabGuillaume Herbreteau, Alexandra Langlais, Laurent Greillier, et al.Clinical Lung Cancer|October 26, 2019
Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE TrialJaafar Bennouna, Nicolas Girard, Clarisse Audigier-Valette, et al.Oncotarget|December 24, 2016
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 TrialGuénaëlle Levallet, Fatéméh Dubois, Pierre Fouret, et al.The European Respiratory Journal|August 12, 2017
EGFR tyrosine kinase inhibitors <i>versus</i> chemotherapy in <i>EGFR</i> wild-type pre-treated advanced nonsmall cell lung cancer in daily practicePascale Tomasini, Solenn Brosseau, Julien Mazières, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2012
An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trialFlorence de Fraipont, Guénaëlle Levallet, Christian Creveuil, et al.The European Respiratory Journal|March 17, 2018
Cost-effectiveness of <i>KRAS</i>, <i>EGFR</i> and <i>ALK</i> testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm studySandrine Loubière, Alexandre Drezet, Michèle Beau-Faller, et al.The European Respiratory Journal|February 7, 2015
BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokersSébastien Couraud, Pierre-Jean Souquet, Christophe Paris, et al.Lung Cancer (Amsterdam, Netherlands)|December 17, 2019
Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France projectMichèle Beau-Faller, Erwan Pencreach, Charlotte Leduc, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 13, 2017
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers FranceNicolas Guibert, Fabrice Barlesi, Renaud Descourt, et al.European Journal of Cancer (Oxford, England : 1990)|June 18, 2025
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDSElisa Gobbini, Alexandra Langlais, Pascale Missy, et al.Pageof 16